CA2946294C - Method for removing bacteria from blood using high flow rate - Google Patents
Method for removing bacteria from blood using high flow rate Download PDFInfo
- Publication number
- CA2946294C CA2946294C CA2946294A CA2946294A CA2946294C CA 2946294 C CA2946294 C CA 2946294C CA 2946294 A CA2946294 A CA 2946294A CA 2946294 A CA2946294 A CA 2946294A CA 2946294 C CA2946294 C CA 2946294C
- Authority
- CA
- Canada
- Prior art keywords
- bacteria
- blood
- sample
- heparin
- media
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 111
- 239000008280 blood Substances 0.000 title claims abstract description 111
- 241000894006 Bacteria Species 0.000 title claims abstract description 106
- 238000000034 method Methods 0.000 title claims abstract description 59
- 238000001179 sorption measurement Methods 0.000 claims abstract description 106
- 229920002971 Heparan sulfate Polymers 0.000 claims abstract description 38
- 241000192125 Firmicutes Species 0.000 claims abstract description 9
- 239000011324 bead Substances 0.000 claims description 88
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 66
- 239000000758 substrate Substances 0.000 claims description 63
- 229960002897 heparin Drugs 0.000 claims description 61
- 229920000669 heparin Polymers 0.000 claims description 56
- 239000003463 adsorbent Substances 0.000 claims description 35
- 239000007787 solid Substances 0.000 claims description 35
- -1 polyethylene Polymers 0.000 claims description 27
- 229920001282 polysaccharide Polymers 0.000 claims description 26
- 150000004676 glycans Chemical class 0.000 claims description 25
- 239000005017 polysaccharide Substances 0.000 claims description 25
- 229920000642 polymer Polymers 0.000 claims description 22
- 239000004698 Polyethylene Substances 0.000 claims description 21
- 229920000573 polyethylene Polymers 0.000 claims description 21
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 20
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims description 17
- 150000001720 carbohydrates Chemical class 0.000 claims description 15
- 235000014633 carbohydrates Nutrition 0.000 claims description 15
- 241000588724 Escherichia coli Species 0.000 claims description 14
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 10
- 241000194031 Enterococcus faecium Species 0.000 claims description 8
- 239000004743 Polypropylene Substances 0.000 claims description 8
- 229920001155 polypropylene Polymers 0.000 claims description 8
- 239000004814 polyurethane Substances 0.000 claims description 8
- 229920002635 polyurethane Polymers 0.000 claims description 8
- 238000001228 spectrum Methods 0.000 claims description 8
- 108090000204 Dipeptidase 1 Proteins 0.000 claims description 7
- 102000006635 beta-lactamase Human genes 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 5
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 5
- 239000005977 Ethylene Substances 0.000 claims description 5
- 229920002873 Polyethylenimine Polymers 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- 239000000178 monomer Substances 0.000 claims description 5
- 229920002367 Polyisobutene Polymers 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 3
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 2
- 238000000159 protein binding assay Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 13
- 238000011282 treatment Methods 0.000 abstract description 8
- 210000002381 plasma Anatomy 0.000 abstract description 5
- 244000052769 pathogen Species 0.000 description 42
- 230000027455 binding Effects 0.000 description 30
- 239000000835 fiber Substances 0.000 description 23
- 239000011148 porous material Substances 0.000 description 18
- 230000005660 hydrophilic surface Effects 0.000 description 16
- 239000002245 particle Substances 0.000 description 16
- 241000191967 Staphylococcus aureus Species 0.000 description 13
- 208000031729 Bacteremia Diseases 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 241000700605 Viruses Species 0.000 description 10
- 244000052616 bacterial pathogen Species 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 241000588722 Escherichia Species 0.000 description 9
- 239000002156 adsorbate Substances 0.000 description 9
- 125000002091 cationic group Chemical group 0.000 description 9
- 238000000502 dialysis Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000012510 hollow fiber Substances 0.000 description 9
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 8
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 229960003085 meticillin Drugs 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 229920000785 ultra high molecular weight polyethylene Polymers 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000002965 anti-thrombogenic effect Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 239000004744 fabric Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000002885 thrombogenetic effect Effects 0.000 description 5
- 241000194032 Enterococcus faecalis Species 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 239000004699 Ultra-high molecular weight polyethylene Substances 0.000 description 4
- 239000002250 absorbent Substances 0.000 description 4
- 230000002745 absorbent Effects 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 description 4
- 239000010408 film Substances 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229920001059 synthetic polymer Polymers 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 241000606161 Chlamydia Species 0.000 description 3
- 241000194033 Enterococcus Species 0.000 description 3
- 241000711549 Hepacivirus C Species 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 3
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000006213 oxygenation reaction Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 229920002492 poly(sulfone) Polymers 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012876 topography Methods 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 206010011409 Cross infection Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- 229920001247 Reticulated foam Polymers 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 238000005056 compaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000004811 fluoropolymer Substances 0.000 description 2
- 229920002313 fluoropolymer Polymers 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 229920002239 polyacrylonitrile Polymers 0.000 description 2
- 239000002952 polymeric resin Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000012286 potassium permanganate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 229920003002 synthetic resin Polymers 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 239000002759 woven fabric Substances 0.000 description 2
- PHOLIFLKGONSGY-CSKARUKUSA-N (e)-(3-methyl-1,3-benzothiazol-2-ylidene)hydrazine Chemical compound C1=CC=C2S\C(=N\N)N(C)C2=C1 PHOLIFLKGONSGY-CSKARUKUSA-N 0.000 description 1
- WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 229920002306 Glycocalyx Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- HWGBHCRJGXAGEU-UHFFFAOYSA-N Methylthiouracil Chemical compound CC1=CC(=O)NC(=S)N1 HWGBHCRJGXAGEU-UHFFFAOYSA-N 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 1
- 241000122971 Stenotrophomonas Species 0.000 description 1
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001312524 Streptococcus viridans Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 102000019361 Syndecan Human genes 0.000 description 1
- 108050006774 Syndecan Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007485 conventional hemodialysis Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 150000002302 glucosamines Chemical class 0.000 description 1
- 210000004517 glycocalyx Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000002373 hemiacetals Chemical class 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 108091000314 heparan sulfate binding proteins Proteins 0.000 description 1
- 102000036064 heparan sulfate binding proteins Human genes 0.000 description 1
- 239000002634 heparin fragment Substances 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000012633 leachable Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002102 nanobead Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920001707 polybutylene terephthalate Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000022218 streptococcal pneumonia Diseases 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3692—Washing or rinsing blood or blood constituents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28002—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their physical properties
- B01J20/28004—Sorbent size or size distribution, e.g. particle size
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
- B01J20/28016—Particle form
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
- B01J20/28023—Fibres or filaments
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3204—Inorganic carriers, supports or substrates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
- B01J20/3208—Polymeric carriers, supports or substrates
- B01J20/321—Polymeric carriers, supports or substrates consisting of a polymer obtained by reactions involving only carbon to carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
- B01J20/3208—Polymeric carriers, supports or substrates
- B01J20/3212—Polymeric carriers, supports or substrates consisting of a polymer obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3268—Macromolecular compounds
- B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
- B01J20/3274—Proteins, nucleic acids, polysaccharides, antibodies or antigens
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3291—Characterised by the shape of the carrier, the coating or the obtained coated product
- B01J20/3293—Coatings on a core, the core being particle or fiber shaped, e.g. encapsulated particles, coated fibers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/0057—Special media to be introduced, removed or treated retained by adsorption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/20—Pathogenic agents
- A61M2202/203—Bacteria
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/50—Aspects relating to the use of sorbent or filter aid materials
- B01J2220/62—In a cartridge
Landscapes
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- External Artificial Organs (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461984013P | 2014-04-24 | 2014-04-24 | |
| US61/984,013 | 2014-04-24 | ||
| PCT/US2015/026340 WO2015164198A1 (en) | 2014-04-24 | 2015-04-17 | Method for removing bacteria from blood using high flow rate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2946294A1 CA2946294A1 (en) | 2015-10-29 |
| CA2946294C true CA2946294C (en) | 2023-03-21 |
Family
ID=54333028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2946294A Active CA2946294C (en) | 2014-04-24 | 2015-04-17 | Method for removing bacteria from blood using high flow rate |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20170035956A1 (enExample) |
| EP (1) | EP3134146B1 (enExample) |
| JP (3) | JP2017513636A (enExample) |
| KR (1) | KR20170020749A (enExample) |
| CN (1) | CN106255520B (enExample) |
| AU (2) | AU2015250107A1 (enExample) |
| BR (1) | BR112016024569B1 (enExample) |
| CA (1) | CA2946294C (enExample) |
| DE (1) | DE15782250T1 (enExample) |
| ES (1) | ES2625351T3 (enExample) |
| MX (1) | MX2016013873A (enExample) |
| WO (1) | WO2015164198A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE029958T2 (en) | 2005-12-13 | 2017-04-28 | Exthera Medical Corp | A method for removing extracellular microbes, inflammatory cells or inflammatory proteins from the body |
| JP5925693B2 (ja) | 2009-12-01 | 2016-05-25 | エクステラ・メディカル・コーポレーション | 表面固定した多糖類を用いた、血液からのサイトカイン除去法 |
| WO2012112724A1 (en) | 2011-02-15 | 2012-08-23 | Exthera Medical, Llc | Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines |
| DK2861273T3 (da) | 2012-06-13 | 2017-11-27 | Exthera Medical Corp | Anvendelse af heparin og kulhydrater til behandling af cancer. |
| EP3013445B1 (en) | 2013-06-24 | 2019-11-06 | ExThera Medical Corporation | Blood filtration system containing mannose coated substrate |
| JP6806563B2 (ja) | 2013-11-08 | 2021-01-06 | エクステラ・メディカル・コーポレーション | 吸着媒体を使用する感染症の診断法 |
| KR20170020749A (ko) | 2014-04-24 | 2017-02-24 | 엑스테라 메디컬 코퍼레이션 | 고유속을 이용한 혈액으로부터 세균의 제거방법 |
| JP7100454B2 (ja) | 2014-09-22 | 2022-07-13 | エクスセラ メディカル コーポレイション | 装着型血液潅流デバイス |
| WO2017151797A1 (en) | 2016-03-02 | 2017-09-08 | Exthera Medical Corporation | Method for treating drug intoxication |
| US11911551B2 (en) | 2016-03-02 | 2024-02-27 | Exthera Medical Corporation | Method for treating drug intoxication |
| CN109562353B (zh) * | 2016-05-26 | 2022-07-15 | 西托索尔本茨公司 | 使用血液相容性多孔聚合物珠吸着剂去除内毒素血症诱导分子 |
| CN109689188A (zh) * | 2016-11-29 | 2019-04-26 | 甘布罗伦迪亚股份公司 | 用于吸附细菌的膜 |
| EP3388140A1 (en) * | 2017-04-10 | 2018-10-17 | Gambro Lundia AB | Extracorporeal blood circuit |
| US20190105475A1 (en) * | 2017-10-05 | 2019-04-11 | Minnetronix, Inc. | Systems, catheters, and methods for treating along the central nervous system |
| EP3735281B1 (en) | 2018-01-05 | 2024-11-27 | Path Ex, Inc. | Device for the capture and removal of disease material from fluids |
| KR20220009400A (ko) | 2019-05-16 | 2022-01-24 | 엑스테라 메디컬 코퍼레이션 | 내피 글리코칼릭스 구조의 조절 방법 |
| KR102419508B1 (ko) * | 2020-10-14 | 2022-07-11 | 대전보건대학교 산학협력단 | 신규한 메티실린-내성 황색포도상구균 검출 방법 및 이의 용도 |
| EP4251230A1 (en) * | 2020-11-30 | 2023-10-04 | Alteco Medical AB | Device for binding and separation of at least one component from a body fluid |
| CN114011389B (zh) * | 2021-12-08 | 2023-10-31 | 广州康盛生物科技股份有限公司 | 一种用于脓毒血症的血液净化材料及其制备方法和应用 |
| KR102863574B1 (ko) * | 2022-12-16 | 2025-09-22 | 서울대학교산학협력단 | 병원 내 2차 감염을 감소시키기 위한 혈액관류장치 |
| WO2024177096A1 (ja) | 2023-02-21 | 2024-08-29 | 東レ株式会社 | 中空糸膜及び中空糸膜モジュール |
| WO2025117428A1 (en) * | 2023-11-29 | 2025-06-05 | Exthera Medical Corporation | Fluidized bed extracorporeal treatment device |
| CN120437731B (zh) * | 2025-07-09 | 2025-11-04 | 天津泰达洁净材料有限公司 | 一种熔喷pbt非织造布复合滤材及其制备方法与应用 |
Family Cites Families (159)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3782382A (en) | 1972-02-03 | 1974-01-01 | K N Enterprises Inc | Means for blood administration and the like |
| US4103685A (en) | 1976-01-05 | 1978-08-01 | Lupien Paul J | Method and apparatus for extravascular treatment of blood |
| JPS54127493U (enExample) | 1978-02-25 | 1979-09-05 | ||
| US4430496A (en) | 1980-01-17 | 1984-02-07 | Varian Associates, Inc. | Strong anion exchange composition and methods |
| US4415665A (en) | 1980-12-12 | 1983-11-15 | Pharmacia Fine Chemicals Ab | Method of covalently binding biologically active organic substances to polymeric substances |
| JPS5853757A (ja) | 1981-09-25 | 1983-03-30 | Denki Kagaku Kogyo Kk | 免疫アフイニテイクロマトグラフイ−用吸着体及びその製法 |
| SE8200751L (sv) | 1982-02-09 | 1983-08-10 | Olle Larm | Forfarande for kovalent koppling for framstellning av konjugat och hervid erhallna produkter |
| JPS58146354A (ja) | 1982-02-26 | 1983-08-31 | 日機装株式会社 | 体液浄化器の製造法 |
| US4820302A (en) | 1982-04-22 | 1989-04-11 | Sterling Drug Inc. | Bio compatible and blood compatible materials and methods |
| CA1221307A (en) | 1982-12-02 | 1987-05-05 | Nobutaka Tani | Adsorbent and process for preparing the same |
| JPS59227827A (ja) | 1983-06-10 | 1984-12-21 | Nippon Koutai Kenkyusho:Kk | マラリア原虫由来糖鎖関連抗原及びその製造法 |
| FR2558063B1 (fr) | 1984-01-18 | 1987-02-20 | Hospal Ind | Rein artificiel a aiguille unique |
| DE3609021A1 (de) | 1985-03-25 | 1986-09-25 | Bio-Rad Laboratories, Inc., Richmond, Calif. | Chromatographisches trennmedium fuer die schnelle analyse von kleinen proben |
| DE3519011A1 (de) | 1985-05-25 | 1986-11-27 | Behringwerke Ag, 3550 Marburg | Verfahren zur herstellung eines materials zur affinitaetschromatographie |
| DE3853219T2 (de) | 1987-11-20 | 1995-06-29 | Kanegafuchi Chemical Ind | Methode zur Entfernung von Serum-Amyloid-Protein. |
| US4955870A (en) | 1988-08-23 | 1990-09-11 | Ridderheim Kristen A | Hypodermic syringe with retractable needle |
| JPH0489500A (ja) | 1990-07-31 | 1992-03-23 | Kirin Brewery Co Ltd | アフィニティクロマトグラフィーによる物質の精製法および精製装置 |
| US5227049A (en) | 1990-08-20 | 1993-07-13 | Hospal Industrie | Single-needle circuit for circulating blood outside the body in blood treatment apparatus |
| FR2672219B1 (fr) | 1991-02-06 | 1998-09-11 | Hospal Ind | Procede de commande de la circulation du sang dans un circuit a aiguille unique. |
| SE469256B (sv) | 1991-02-18 | 1993-06-14 | Medscand Ab | Rengoeringsprodukt |
| AU648655B2 (en) | 1991-03-26 | 1994-04-28 | Otsuka Pharmaceutical Factory, Inc. | Adsorbed cellular fibronectin and process for separating and purifying fibronectins |
| US5211850A (en) | 1991-07-26 | 1993-05-18 | Research Medical, Inc. | Plasma filter sorbent system for removal of components from blood |
| DE4217917A1 (de) | 1992-05-30 | 1993-12-02 | Job Prof Dr Med Harenberg | Immobilisation von chemisch kovalent gebundenem Heparin an Polymere mit Arylresten im Polymer |
| DE4331358A1 (de) | 1992-10-12 | 1994-04-14 | Braun Melsungen Ag | Verfahren zur quantitativen selektiven Entfernung oder präparativen Gewinnung von Tumor-Nekrose-Faktor (TNF) oder/und Lipopolysacchariden (LPS) aus wäßrigen Flüssigkeiten |
| US5344455A (en) * | 1992-10-30 | 1994-09-06 | Medtronic, Inc. | Graft polymer articles having bioactive surfaces |
| US5437861A (en) | 1993-03-16 | 1995-08-01 | Applied Immune Sciences, Inc. | Removal of selected factors from whole blood or its components; and prevention and treatment of septic shock syndrome |
| NO931809L (no) | 1993-05-19 | 1994-11-21 | Norsk Hydro As | Hemofilter |
| US5447859A (en) | 1993-07-16 | 1995-09-05 | Viagene | Method for the purification or removal of retroviruses using sulfated cellulose |
| US5753227A (en) | 1993-07-23 | 1998-05-19 | Strahilevitz; Meir | Extracorporeal affinity adsorption methods for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases |
| WO1995005400A1 (en) | 1993-08-19 | 1995-02-23 | Minnesota Mining And Manufacturing Company | Heparin functional affinity supports |
| JPH07178161A (ja) | 1993-12-24 | 1995-07-18 | Terumo Corp | 医療器具 |
| SE9501056D0 (sv) | 1995-03-23 | 1995-03-23 | Probi Ab | Epithelial adherent lactobacilli |
| US6312907B1 (en) | 1995-04-24 | 2001-11-06 | The Texas A & M University System | DbpA compositions and methods of use |
| DE19515554C2 (de) | 1995-04-27 | 1999-06-17 | Braun Melsungen Ag | Verwendung eines Mittels und Vorrichtung zur simultanen extrakorporalen Elimination von Tumor-Nekrose-Faktor alpha und bakteriellen Lipopolysacchariden aus Vollblut oder/und Blutplasma |
| US6544727B1 (en) | 1995-06-07 | 2003-04-08 | Cerus Corporation | Methods and devices for the removal of psoralens from blood products |
| EP0840781B1 (en) | 1995-06-07 | 2009-12-09 | Cerus Corporation | Methods and devices for the removal of psoralens from blood products |
| WO1997000969A1 (de) | 1995-06-20 | 1997-01-09 | Johannes Schumacher | Verfahren und vorrichtung zur bestimmung der aktivität von enzymen in flüssigkeiten, beziehungsweise der konzentration und/oder aktivität von inhibitoren in flüssigkeiten |
| DE69722491T2 (de) | 1996-03-18 | 2004-05-19 | Kaneka Corp. | Adsorbens und Verfahren zur Entfernung von Chemokinen des CC-Subtyps aus Körperflüssigkeiten |
| RU2089283C1 (ru) | 1996-03-23 | 1997-09-10 | Научно-исследовательская фирма "Ультрасан" | Био-, гемосовместимые сорбенты на основе сверхсшитых полимеров стирола с модифицированной поверхностью, способ их получения (варианты) и способ получения матрицы сорбента |
| SE507028C2 (sv) | 1996-08-06 | 1998-03-16 | Medicarb Ab | Ny medicinsk användning |
| AU5811498A (en) | 1996-12-31 | 1998-07-31 | Robert L. Stephon | Microsphere-enhanced immunoassay for the detection of veterinary diseases |
| US20010009756A1 (en) | 1998-01-06 | 2001-07-26 | Derek Hei | Flow devices for the reduction of compounds from biological compositions and methods of use |
| US20010018179A1 (en) | 1998-01-06 | 2001-08-30 | Derek J. Hei | Batch devices for the reduction of compounds from biological compositions containing cells and methods of use |
| KR20060015703A (ko) | 1997-03-25 | 2006-02-17 | 카네카 코포레이션 | C형 간염 바이러스 제거용 흡착재, 흡착장치 및 흡착방법 |
| ES2251090T3 (es) | 1997-05-27 | 2006-04-16 | Sanofi-Aventis | Dispositivo y metodo para aplicar articulos planos. |
| US6465170B2 (en) | 1997-06-13 | 2002-10-15 | Baxter Aktiengesellschaft | Method for depleting viral and molecular pathogens in a biological material |
| US6197568B1 (en) | 1997-07-29 | 2001-03-06 | The Regents Of The University Of Michigan | Method and compositions for isolation, diagnosis and treatment of polyanion-binding microorganisms |
| US20020197249A1 (en) | 2001-04-10 | 2002-12-26 | Renal Tech International | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood products |
| US20020197250A1 (en) | 2001-04-10 | 2002-12-26 | Renal Tech International | Biocompatible devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood |
| US20020159995A1 (en) | 1997-07-30 | 2002-10-31 | Renal Tech International | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, generated as a result of extracorporeal blood processing |
| US6053894A (en) | 1997-08-04 | 2000-04-25 | Shadd, Jr.; Daniel L. | Hypodermic syringe |
| US7611831B2 (en) | 1998-01-06 | 2009-11-03 | Cerus Corporation | Adsorbing pathogen-inactivating compounds with porous particles immobilized in a matrix |
| US6136424A (en) | 1998-02-06 | 2000-10-24 | Renal Tech International, Llc | Method of and material for purification of physiological liquids of organism, and method of producing the material |
| GB9804632D0 (en) | 1998-03-05 | 1998-04-29 | Cantab Pharma Res | Virus preparations and methods |
| US8197430B1 (en) | 1998-05-22 | 2012-06-12 | Biopheresis Technologies, Inc. | Method and system to remove cytokine inhibitor in patients |
| US6248127B1 (en) | 1998-08-21 | 2001-06-19 | Medtronic Ave, Inc. | Thromboresistant coated medical device |
| JP2000086688A (ja) | 1998-09-04 | 2000-03-28 | Ngk Insulators Ltd | パルボウイルス吸着糖鎖リガンドおよびこれを利用したパルボウイルス除去装置 |
| NO984143L (no) | 1998-09-09 | 2000-03-10 | Norsk Hydro As | Ny prosess for å fremstille overflatemodifiserende stoffer |
| WO2000023792A1 (en) | 1998-10-19 | 2000-04-27 | Cbd Technologies Ltd. | Methods of concentrating microorganisms using affinity separation |
| CA2322000C (en) | 1998-12-24 | 2008-07-29 | Toray Industries, Inc. | Hemocathartic method and hemocathartic column |
| JP2000217575A (ja) | 1999-02-01 | 2000-08-08 | Masashi Funayama | 生理活性物質、ヒト血球分化細胞およびヒト細胞の吸着体。 |
| DE19916352A1 (de) | 1999-04-12 | 2000-10-19 | Braun Melsungen Ag | Entfernung von hüllehaltigen Viren aus Blut, Plasma oder Serum |
| SE515295C2 (sv) | 1999-11-23 | 2001-07-09 | Medicarb Ab | Förfarande för framställning av konjugat av en biologiskt aktiv polysackarid och ett fast substrat, samt sådana konjugat |
| JP2001178817A (ja) | 1999-12-24 | 2001-07-03 | Terumo Corp | 人工腎臓用装置およびこれを用いた品質評価装置ならびに流体回路 |
| US7067060B2 (en) * | 2000-01-11 | 2006-06-27 | Nephros, Inc. | Ionic enhanced dialysis/diafiltration system |
| JP2001190273A (ja) | 2000-01-14 | 2001-07-17 | Jsr Corp | ウイルス濃縮用粒子、該粒子を使用するウイルス濃縮方法およびウイルス検出方法 |
| GB0001450D0 (en) | 2000-01-21 | 2000-03-08 | Genpoint As | Cell isolation method |
| DE60035127T2 (de) | 2000-03-06 | 2008-02-14 | Dade Behring Marburg Gmbh | Mit polysacchariden beschichtete träger, deren herstellung und verwendung |
| US20020164644A1 (en) | 2000-04-05 | 2002-11-07 | Ikuro Maruyama | Adsorbents for high mobility group proteins and column for purifying body fluid |
| US7181261B2 (en) | 2000-05-15 | 2007-02-20 | Silver James H | Implantable, retrievable, thrombus minimizing sensors |
| DE10045434B4 (de) | 2000-09-14 | 2005-07-14 | Fresenius Hemocare Gmbh | Adsorbens mit unterschiedlich modifizierten Oberflächenbereichen, Verfahren zu dessen Herstellung und Verwendung davon |
| JP4283430B2 (ja) | 2000-09-26 | 2009-06-24 | 株式会社カネカ | エンテロトキシンの吸着材、吸着除去方法および吸着器 |
| US8153121B2 (en) | 2000-10-06 | 2012-04-10 | Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center | Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders |
| US8178304B2 (en) | 2000-10-06 | 2012-05-15 | Smith Terry J | Diagnostic methods relating to Graves' disease and other autoimmune disorders |
| US6509104B2 (en) | 2000-12-05 | 2003-01-21 | Michigan Biotechnology Institute | Antithrombogenic polymer coating |
| EP1884274A1 (en) | 2000-12-29 | 2008-02-06 | Upfront Chromatography A/S | Extracorporeal capturing of specific bio-macromolecular entities from extracellular body fluids |
| KR100804542B1 (ko) | 2001-01-30 | 2008-02-20 | 가부시키가이샤 가네카 | 직접 혈액관류가 가능한 체액 처리기 |
| DE10117043A1 (de) | 2001-04-05 | 2002-11-07 | Gerhard Puetz | Verfahren zur Eliminierung von potentiell toxischen und/oder schädlichen Stoffen |
| US20020197252A1 (en) | 2001-04-10 | 2002-12-26 | Renal Tech International | Selective adsorption devices and systems |
| US6773412B2 (en) | 2001-04-13 | 2004-08-10 | Chf Solutions, Inc. | User interface for blood treatment device |
| EP1435263A1 (en) | 2001-10-10 | 2004-07-07 | Noritake Co., Limited | Photocatalytic material selectively inactivating biologically harmful substance and utilization thereof |
| JP2003128502A (ja) | 2001-10-18 | 2003-05-08 | Noritake Co Ltd | 有害物質の処理材およびその製造方法 |
| US8980568B2 (en) | 2001-10-11 | 2015-03-17 | Aviva Biosciences Corporation | Methods and compositions for detecting non-hematopoietic cells from a blood sample |
| US20030148017A1 (en) | 2001-12-07 | 2003-08-07 | Olli Tuominen | Copolymer coating for a hydrophobic membrane |
| WO2003078023A1 (en) | 2002-03-14 | 2003-09-25 | Baxter International Inc. | Compound removal device |
| EP1507557A4 (en) | 2002-04-23 | 2006-06-14 | Meir Strahilevitz | METHODS AND DEVICES FOR TARGETING A SITE IN A MAMMAL AND DETERMINING CHEMICAL SPECIES FROM A MAMMAL |
| US7488309B2 (en) | 2002-07-03 | 2009-02-10 | Bioanalytical Systems, Inc. | Device and method for drug delivery to animals |
| US20050249724A1 (en) | 2002-07-11 | 2005-11-10 | Upfront Chromatography A/S | Extracorporeal stablised expanded bed adsorption method for the treatment of sepsis |
| ATE426808T1 (de) | 2002-07-24 | 2009-04-15 | Bio Rad Laboratories | Proteininteraktionsdifferenzabbildung |
| WO2005021799A2 (en) | 2003-08-15 | 2005-03-10 | University Of South Florida | Materials and methods for capture of pathogens and removal of aurintricarboxylic acid from a sample |
| US20040182783A1 (en) | 2003-03-17 | 2004-09-23 | Walker Kimberly A. | Filter and concentrator device for treatment of blood |
| US7207964B2 (en) * | 2003-03-17 | 2007-04-24 | Hemavation, Llc | Apparatus and method for down-regulating immune system mediators in blood |
| US7399400B2 (en) | 2003-09-30 | 2008-07-15 | Nano-Proprietary, Inc. | Nanobiosensor and carbon nanotube thin film transistors |
| WO2005051313A2 (en) | 2003-11-19 | 2005-06-09 | Chiron Corporation | Methods and reagents for treating, preventing and diagnosing bunyavirus infection |
| US7540958B2 (en) | 2004-03-08 | 2009-06-02 | Gambro Lundia Ab | Device for controlling blood circulation for a single needle circuit |
| WO2006093524A2 (en) | 2004-07-16 | 2006-09-08 | The General Hospital Corporation | Antigen-carbohydrate conjugates |
| WO2006009179A1 (ja) | 2004-07-23 | 2006-01-26 | Kaneka Corporation | 水不溶性微粒子を除去した吸着材を充填した直接血液灌流用吸着器、および水不溶性微粒子を除去した直接血液灌流用吸着材の取得方法 |
| DE102004037475A1 (de) | 2004-07-30 | 2006-03-23 | Heinrich, Hans-Werner, Prof. Dr. | Filtersystem zur membrangetrennten, adsorptiven Behandlung partikelhaltiger Flüssigkeiten |
| US20060030027A1 (en) | 2004-08-04 | 2006-02-09 | Aspira Biosystems, Inc. | Capture and removal of biomolecules from body fluids using partial molecular imprints |
| WO2006025371A1 (ja) | 2004-08-30 | 2006-03-09 | Kaneka Corporation | 顆粒球吸着材 |
| US8445293B2 (en) | 2005-02-09 | 2013-05-21 | Rapid Pathogen Screening, Inc. | Method to increase specificity and/or accuracy of lateral flow immunoassays |
| GB0509433D0 (en) | 2005-05-09 | 2005-06-15 | Uni For Milj Og Biovitenskap | Method |
| US20100291588A1 (en) | 2005-06-24 | 2010-11-18 | The Board Of Regents Of The University Of Texas System | Systems and methods including self-contained cartridges with detection systems and fluid delivery systems |
| US20100239673A1 (en) | 2005-08-01 | 2010-09-23 | Linhardt Robert J | Blood compatible nanomaterials and methods of making and using the same |
| WO2007058592A1 (en) | 2005-11-21 | 2007-05-24 | Ge Healthcare Bio-Sciences Ab | A method of chromatography using semi-synthetic heparin ligands |
| HUE029958T2 (en) | 2005-12-13 | 2017-04-28 | Exthera Medical Corp | A method for removing extracellular microbes, inflammatory cells or inflammatory proteins from the body |
| WO2008057111A2 (en) | 2005-12-21 | 2008-05-15 | Meso Scale Technologies, Llc | Assay apparatuses, methods and reagents |
| US8211048B2 (en) | 2006-02-22 | 2012-07-03 | Henry Ford Health System | System and method for delivery of regional citrate anticoagulation to extracorporeal blood circuits |
| US7763097B2 (en) | 2006-06-08 | 2010-07-27 | University of Pittsburgh—of the Commonwealth System of Higher Education | Devices, systems and methods for reducing the concentration of a chemical entity in fluids |
| JP4934133B2 (ja) | 2006-06-16 | 2012-05-16 | テルモ株式会社 | 血液処理フィルターおよび血液処理回路 |
| FR2902670B1 (fr) | 2006-06-22 | 2009-04-24 | Gambro Lundia Ab | Utilisation d'une suspension pour traiter un support a usage medical, support a usage medical, echangeur et dispositif d'adsorption comprenant le support |
| WO2008147382A1 (en) | 2006-09-27 | 2008-12-04 | Micronics, Inc. | Integrated microfluidic assay devices and methods |
| CA2667012A1 (en) | 2006-10-26 | 2008-05-02 | Abbott Laboratories | Immunoassay of analytes in samples containing endogenous anti-analyte antibodies |
| GB0702183D0 (en) | 2007-02-05 | 2007-03-14 | Iti Scotland Ltd | Pathogen binding |
| WO2008128251A1 (en) | 2007-04-17 | 2008-10-23 | The Children's Hospital Of Philadelphia | Humanized viral vectors and methods of use thereof |
| AU2008242142A1 (en) | 2007-04-19 | 2008-10-30 | C.G.M.3 Ltd | Device system and method for monitoring and controlling blood analyte levels |
| CA2690401C (en) * | 2007-06-18 | 2016-10-18 | Olle Larm | Device and method for restoration of the condition of blood |
| WO2008155683A1 (en) | 2007-06-18 | 2008-12-24 | Firmenich Sa | Malodor counteracting compositions and method for their use |
| JP4226050B1 (ja) | 2007-09-12 | 2009-02-18 | 株式会社Reiメディカル | 体液浄化処理用吸着カラム |
| WO2009086343A2 (en) | 2007-12-31 | 2009-07-09 | 3M Innovative Properties Company | Microorganism-capturing compositions and methods |
| US11051733B2 (en) | 2008-01-18 | 2021-07-06 | Wake Forest University Health Sciences | Isolating and purifying cells for therapy |
| EP2087916A1 (en) | 2008-02-11 | 2009-08-12 | ICinnovation BV | Electrosorption device for the purification of blood and other fluids |
| CN101632686A (zh) | 2008-04-04 | 2010-01-27 | 马斯特里赫特大学 | 糖胺聚糖用于修复糖萼的用途 |
| ES2821448T3 (es) | 2008-06-23 | 2021-04-26 | Temasek Polytechnic | Sorbente para un dispositivo de diálisis |
| US20100021622A1 (en) | 2008-07-24 | 2010-01-28 | National Chiao Tung University | Apparatus and method for forming multilayer polymer thin film |
| US20100040546A1 (en) | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
| WO2010029317A2 (en) | 2008-09-10 | 2010-03-18 | Ibd Column Therapies International Ab | Treating inflammatory conditions |
| US8310415B2 (en) | 2008-09-30 | 2012-11-13 | Animas Corporation | Medical devices using bistable displays |
| US8454547B2 (en) | 2009-02-25 | 2013-06-04 | The Invention Science Fund I, Llc | Device, system, and method for controllably reducing inflammatory mediators in a subject |
| US8801922B2 (en) | 2009-06-24 | 2014-08-12 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Dialysis system |
| US20120219561A1 (en) | 2009-07-31 | 2012-08-30 | Ingeneron, Inc. | Prophylaxis Against Cancer Metastasis |
| JP5925693B2 (ja) * | 2009-12-01 | 2016-05-25 | エクステラ・メディカル・コーポレーション | 表面固定した多糖類を用いた、血液からのサイトカイン除去法 |
| US8366649B2 (en) | 2009-12-09 | 2013-02-05 | Araz Ibragimov | Manually operated disposable single-needle circuit for extracorporeal treatment of blood |
| AU2011215942B8 (en) | 2010-02-09 | 2014-02-13 | Exthera Medical Corporation | Removal of virulence factors through extracorporeal therapy |
| US20130102948A1 (en) | 2010-04-19 | 2013-04-25 | Ilan K. Reich | Portable blood filtration devices, systems, and methods |
| CA2814586C (en) * | 2010-10-15 | 2024-01-30 | Cytopherx, Inc. | Cytopheretic cartridge and use thereof |
| WO2012112724A1 (en) * | 2011-02-15 | 2012-08-23 | Exthera Medical, Llc | Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines |
| US20130131423A1 (en) * | 2011-04-12 | 2013-05-23 | Tianxin Wang | Methods to detect and treat diseases |
| DK2717941T3 (da) | 2011-06-13 | 2020-07-13 | Tla Targeted Immunotherapies Ab | Behandling af cancer |
| EP3081937B1 (en) | 2011-07-18 | 2019-11-13 | President and Fellows of Harvard College | Engineered microbe-targeting molecules and uses thereof |
| EP2556849A1 (en) | 2011-08-08 | 2013-02-13 | Gambro Lundia AB | Separation material |
| DK2861273T3 (da) | 2012-06-13 | 2017-11-27 | Exthera Medical Corp | Anvendelse af heparin og kulhydrater til behandling af cancer. |
| US9717841B2 (en) | 2012-09-11 | 2017-08-01 | Gary L. McNeil | Closed-circuit device and methods for isolation, modification, and re-administration of specific constituents from a biological fluid source |
| WO2014085713A1 (en) | 2012-11-30 | 2014-06-05 | The Methodist Hospital Research Institute | Methods and compositions for detecting tuberculosis |
| EP3013445B1 (en) | 2013-06-24 | 2019-11-06 | ExThera Medical Corporation | Blood filtration system containing mannose coated substrate |
| US9850203B2 (en) | 2013-09-26 | 2017-12-26 | Pharmakea, Inc. | Autotaxin inhibitor compounds |
| JP6806563B2 (ja) | 2013-11-08 | 2021-01-06 | エクステラ・メディカル・コーポレーション | 吸着媒体を使用する感染症の診断法 |
| KR20170020749A (ko) | 2014-04-24 | 2017-02-24 | 엑스테라 메디컬 코퍼레이션 | 고유속을 이용한 혈액으로부터 세균의 제거방법 |
| JP7100454B2 (ja) | 2014-09-22 | 2022-07-13 | エクスセラ メディカル コーポレイション | 装着型血液潅流デバイス |
| WO2016164643A1 (en) | 2015-04-07 | 2016-10-13 | Nxstage Medical, Inc. | Blood treatment device priming devices, methods, and systems |
| WO2017001357A1 (en) | 2015-06-29 | 2017-01-05 | Gambro Lundia Ab | Extracorporeal blood treatment apparatus for single-needle treatments |
| WO2017151797A1 (en) | 2016-03-02 | 2017-09-08 | Exthera Medical Corporation | Method for treating drug intoxication |
| US9694344B2 (en) | 2016-05-02 | 2017-07-04 | LiSo Plastics, L.L.C. | Multilayer polymeric membrane and process |
| CN206345699U (zh) | 2016-09-13 | 2017-07-21 | 南京佳乐净膜科技有限公司 | 一种具有长效反冲洗功能的多级复合超微滤膜滤芯 |
| US20200023001A1 (en) | 2018-07-20 | 2020-01-23 | Northeastern University | GlycoFix (Structurally And Functionally Repaired Endothelial Glycocalyx) |
| KR20220009400A (ko) | 2019-05-16 | 2022-01-24 | 엑스테라 메디컬 코퍼레이션 | 내피 글리코칼릭스 구조의 조절 방법 |
| EP4073254B1 (en) | 2019-12-12 | 2025-05-21 | Stavro Medical, Inc. | Extracorporeal blood treatment systems and methods employing batch processing |
| EP4072613A4 (en) | 2019-12-12 | 2024-06-05 | Stavro Medical, Inc. | SYRINGE-BASED SYSTEMS FOR MANUAL EXTRACORPOREAL BLOOD TREATMENT AND BATCH PROCESSING METHODS |
| MX2023010736A (es) | 2021-04-06 | 2023-09-20 | Exthera Medical Corp | Medios de filtracion. |
-
2015
- 2015-04-17 KR KR1020167032452A patent/KR20170020749A/ko not_active Ceased
- 2015-04-17 EP EP15782250.3A patent/EP3134146B1/en active Active
- 2015-04-17 ES ES15782250T patent/ES2625351T3/es active Active
- 2015-04-17 MX MX2016013873A patent/MX2016013873A/es unknown
- 2015-04-17 BR BR112016024569-5A patent/BR112016024569B1/pt active IP Right Grant
- 2015-04-17 CA CA2946294A patent/CA2946294C/en active Active
- 2015-04-17 CN CN201580020663.2A patent/CN106255520B/zh active Active
- 2015-04-17 JP JP2016564198A patent/JP2017513636A/ja not_active Withdrawn
- 2015-04-17 DE DE15782250.3T patent/DE15782250T1/de active Pending
- 2015-04-17 WO PCT/US2015/026340 patent/WO2015164198A1/en not_active Ceased
- 2015-04-17 AU AU2015250107A patent/AU2015250107A1/en not_active Abandoned
-
2016
- 2016-10-24 US US15/332,801 patent/US20170035956A1/en not_active Abandoned
-
2019
- 2019-12-19 US US16/720,720 patent/US11844895B2/en active Active
-
2020
- 2020-01-03 AU AU2020200029A patent/AU2020200029B2/en active Active
- 2020-12-01 JP JP2020199557A patent/JP7184864B2/ja active Active
-
2022
- 2022-06-07 JP JP2022092455A patent/JP2022125040A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20170035956A1 (en) | 2017-02-09 |
| BR112016024569B1 (pt) | 2023-01-03 |
| AU2020200029B2 (en) | 2022-07-28 |
| JP7184864B2 (ja) | 2022-12-06 |
| US11844895B2 (en) | 2023-12-19 |
| KR20170020749A (ko) | 2017-02-24 |
| CN106255520B (zh) | 2022-08-12 |
| JP2021045573A (ja) | 2021-03-25 |
| MX2016013873A (es) | 2017-03-09 |
| EP3134146B1 (en) | 2024-12-25 |
| JP2017513636A (ja) | 2017-06-01 |
| ES2625351T3 (en) | 2025-04-07 |
| AU2015250107A1 (en) | 2016-11-17 |
| JP2022125040A (ja) | 2022-08-26 |
| CN106255520A (zh) | 2016-12-21 |
| DE15782250T1 (de) | 2017-08-10 |
| CA2946294A1 (en) | 2015-10-29 |
| EP3134146A4 (en) | 2018-01-10 |
| WO2015164198A1 (en) | 2015-10-29 |
| BR112016024569A2 (pt) | 2017-08-15 |
| AU2020200029A1 (en) | 2020-01-30 |
| US20200171233A1 (en) | 2020-06-04 |
| BR112016024569A8 (pt) | 2021-06-01 |
| ES2625351T1 (es) | 2017-07-19 |
| EP3134146A1 (en) | 2017-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11844895B2 (en) | Method for removing bacteria from blood using high flow rate | |
| US11123466B2 (en) | Methods for removing cytokines from blood with surface immobilized polysaccharides | |
| US11266772B2 (en) | Use of heparin and carbohydrates to treat cancer | |
| HK1231791B (en) | Method for removing bacteria from blood using high flow rate | |
| HK1231791A1 (en) | Method for removing bacteria from blood using high flow rate | |
| AU2014277852B2 (en) | Method for removing cytokines from blood with surface immobilized polysaccharides | |
| HK1230116B (zh) | 使用固定於表面的多糖从血液中去除细胞因子的方法 | |
| HK1177151B (en) | Method for removing cytokines from blood with surface immobilized polysaccharides | |
| HK1230116A1 (en) | Method for removing cytokines from blood with surface immobilized polysaccharides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200408 |
|
| EEER | Examination request |
Effective date: 20200408 |
|
| EEER | Examination request |
Effective date: 20200408 |
|
| EEER | Examination request |
Effective date: 20200408 |
|
| EEER | Examination request |
Effective date: 20200408 |
|
| EEER | Examination request |
Effective date: 20200408 |